Biogen, Stoke Therapeutics and epilepsy
Shares of Biogen Inc. BIIB rallied 2.60% to $140.64 Friday, on what proved to be an all-around grim trading session for the ...
Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the ...
The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...
Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for ...
Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...
Biogen has bagged $250 million to advance a key pipeline prospect. | Biogen has bagged $250 million to advance a key pipeline ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...
Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “neutral” rating reiterated by equities research analysts at Piper ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results